Menu

Identifying Patients at High Risk of COVID-19 Complications: Considerations for Community Care to Reduce Morbidity, Mortality, and Hospitalization Risk

When:
January 31, 2023 @ 6:09 pm – January 31, 2024 @ 7:09 pm
2023-01-31T18:09:00-01:00
2024-01-31T19:09:00-01:00

Identifying Patients at High Risk of COVID-19 Complications: Considerations for Community Care to Reduce Morbidity, Mortality, and Hospitalization Risk

View ActivityPoster Portal
Downloadable Case Study 1Downloadable Case Study 2

PROGRAM CHAIR

 

Ann E. Woolley, MD, MPH
Associate Clinical Director of Transplant Infectious Diseases

Brigham and Women’s Hospital and Harvard Medical School
Boston, MA

PROGRAM OVERVIEW

This program uses a game-based approach to explore the current understanding of COVID risk assessment, diagnosis, and outpatient treatment.

TARGET AUDIENCE

This activity is designed to meet the educational needs of primary care physicians, internists, pharmacists, nurses, nurse practitioners, physician assistants, and other members of the multidisciplinary team to ensure optimal patient outcomes in outpatient management of COVID-19 infection and potential complications of disease in at-risk populations.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess current best practices in the identification of patients in the community setting at risk of developing serious complications following COVID-19 infection
  • Evaluate specific interventions for reducing the risk of hospitalization and death in at-risk non-hospitalized patients with COVID-19 infection
  • Review clinical guidance regarding appropriate treatment strategies in non-hospitalized patients at risk of serious complications of COVID-19

ACCREDITATION STATEMENT
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in this enduring activity.

NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with COVID-19.

CNE Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT
Ultimate Medical Academy/CCM is accredited as a provider of nursing continuing professional education development by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour of continuing nursing education for RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Faculty Member Disclosures
Ann E. Woolley, MD, MPH Dr. Woolley has nothing to disclose.

All relevant financial relationships have been mitigated.

CME Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.

Douglas Cox, MSN, MHA, RN
Ultimate Medical Academy/CCM – Lead Nurse Planner

The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME/CE activity:

Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Douglas Cox, MSN, MHA, RN, has nothing to disclose.
Debra Gordon, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Daniel DaSilva, Accreditation and Outcomes Coordinator, has nothing to disclose.
Rashado Coote, Program Coordinator, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures
  2. Participate in the enduring activity
  3. Complete the online post-test and evaluation

You will receive your certificate as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based.

This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at mailto:[email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

Copyright © 2023 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

View ActivityPoster Portal
Downloadable Case Study 1Downloadable Case Study 2

Scroll to Top
Menu

Updates in the Treatment and Prevention of COVID-19​

Molnupiravir, an Oral Antiviral, Reduced the Risk of Hospitalization or Death in Patients with Mild-to-Moderate COVID-19

Molnupiravir, an investigational oral antiviral medicine, significantly reduced the risk of hospitalization or death by 50% in an interim analysis of the phase 3 MOVe-OUT trial. The planned analysis evaluated data from 775 at-risk, non-hospitalized adult patients with mild-to-moderate COVID-19. All patients enrolled had at least one risk factor associated with poor COVID-19 outcomes and were randomized within 5 days of symptom onset. At day 29, 7.3% of patients who received molnupiravir were either hospitalized or died, compared with 14.1% of placebo-treated patients (P= .0012). No deaths were reported in patients receiving molnupiravir, compared with 8 deaths in patients who received placebo. The incidence of any adverse event was comparable in the molnupiravir and placebo groups (35% and 40%, respectively). Discontinuation due to adverse events was lower with molnupiravir (1.3%) versus placebo (3.4%).

Reference:

https://www.contagionlive.com/view/molnupiravir-could-become-first-authorized-covid-19-pill